|

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

RECRUITINGPhase 2Sponsored by Chinese University of Hong Kong
Actively Recruiting
PhasePhase 2
SponsorChinese University of Hong Kong
Started2026-10-05
Est. completion2027-12-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

1. Patients aged at least 18 years old on the index date
2. Histologically confirmed prostatic adenocarcinoma with localised or metastatic disease
3. Karnofsky index score of 70% or more
4. Started on androgen deprivation therapy (both medical or surgical), for at least 3 months at baseline
5. Baseline daily hot flush score ≥4

Exclusion Criteria:

1. Patients treated with drugs related to the study medications or with potential effect for vasomotor symptoms, including selective serotonin-re-uptake inhibitors, steroid hormones, clonidine, gabapentin, veralipride, or β-alanine
2. Concomitant use of CYP1A2 inhibitors, e.g. fluoroquinolone, fluovoxamine, cimetidine, propranolol, verapamil, acyclovir, allopurinol, theophylline, etc.
3. Active liver disease including:

   \- cirrhosis - liver failure - jaundice - elevated total or direct bilirubin - abnormal ALT / AST - abnormal INR
4. Severe (eGFR 15 to less than 30 mL/min/1.73 m2) renal impairment or end-stage renal disease (eGFR less than 15 mL/min/1.73 m2)

Conditions3

CancerProstate CancerVasomotor Symptoms

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.